{
    "xml": "<topic id=\"PHP1513\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/rivaroxaban\" basename=\"rivaroxaban\" title=\"RIVAROXABAN\">\n<title>RIVAROXABAN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1136\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/rivaroxaban\">Rivaroxaban</xref>\n</p>\n<data name=\"vtmid\">442539005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_541694731\" title=\"Factor Xa inhibitors\">Factor Xa inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP56133\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/rivaroxaban\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Rivaroxaban is a direct inhibitor of activated factor X (factor Xa).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56078\" outputclass=\"indicationsAndDose\" rev=\"1.33\" parent=\"/drugs/rivaroxaban\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following knee replacement surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;mg once daily for 2 weeks, to be started 6&#8211;10 hours after surgery.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following hip replacement surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;mg once daily for 5 weeks, to be started 6&#8211;10 hours after surgery.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Initial treatment of deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Initial treatment of pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 15&#8239;mg twice daily for 21 days, to be taken with food.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Continued treatment of deep-vein thrombosis (following initial treatment)</p>\n<p outputclass=\"therapeuticIndication\">Continued treatment of pulmonary embolism (following initial treatment)</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg once daily, to be taken with food.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age &#8805; 75 years, or diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg once daily, to be taken with food.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of atherothrombotic events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg twice daily usual duration 12 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>For information on changing from, or to, other anticoagulants&#8212;consult product literature.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56151\" outputclass=\"contraindications\" rev=\"1.27\" parent=\"/drugs/rivaroxaban\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active bleeding</ph>; <ph outputclass=\"contraindication\">in <i>acute coronary syndrome</i>&#8212;previous stroke</ph>; <ph outputclass=\"contraindication\">in <i>acute coronary syndrome</i>&#8212;transient ischaemic attack</ph>; <ph outputclass=\"contraindication\">malignant neoplasms</ph>; <ph outputclass=\"contraindication\">oesophageal varices</ph>; <ph outputclass=\"contraindication\">recent brain surgery</ph>; <ph outputclass=\"contraindication\">recent gastro-intestinal ulcer</ph>; <ph outputclass=\"contraindication\">recent intracranial haemorrhage</ph>; <ph outputclass=\"contraindication\">recent ophthalmic surgery</ph>; <ph outputclass=\"contraindication\">recent spine surgery</ph>; <ph outputclass=\"contraindication\">significant risk of major bleeding</ph>; <ph outputclass=\"contraindication\">vascular aneurysm</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56166\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/rivaroxaban\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait at least 18 hours after rivaroxaban dose before removing catheter and do not give next dose until at least 6 hours after catheter removal)</ph>; <ph outputclass=\"caution\">bronchiectasis</ph>; <ph outputclass=\"caution\">prosthetic heart valve (efficacy not established)</ph>; <ph outputclass=\"caution\">risk of bleeding</ph>; <ph outputclass=\"caution\">rivaroxaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy</ph>; <ph outputclass=\"caution\">severe hypertension</ph>; <ph outputclass=\"caution\">vascular retinopathy</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56068\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/rivaroxaban\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (rivaroxaban).</p>\n<p>Caution in concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55994\" outputclass=\"sideEffects\" rev=\"1.22\" parent=\"/drugs/rivaroxaban\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pain in extremities</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">renal impairment</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Angioedema</ph>; <ph outputclass=\"sideEffect\">dry mouth</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">syncope</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>; <ph outputclass=\"sideEffect\">thrombocythaemia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Jaundice</ph>; <ph outputclass=\"sideEffect\">oedema</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56057\" outputclass=\"pregnancy\" parent=\"/drugs/rivaroxaban\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56171\" outputclass=\"breastFeeding\" parent=\"/drugs/rivaroxaban\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56110\" outputclass=\"hepaticImpairment\" parent=\"/drugs/rivaroxaban\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in liver disease with coagulopathy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56020\" outputclass=\"renalImpairment\" parent=\"/drugs/rivaroxaban\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>For <i>treatment of deep-vein thrombosis or pulmonary embolism and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism</i>, initially 15&#8239;mg twice daily for 21 days, then 20&#8239;mg once daily (but consider reducing to 15&#8239;mg once daily if risk of bleeding outweighs risk of recurrent deep-vein thrombosis or pulmonary embolism) if creatinine clearance 15&#8211;49&#8239;mL/minute.</p>\n<p>For <i>prophylaxis of stroke and systemic embolism in atrial fibrillation,</i> reduce dose to 15&#8239;mg once daily if creatinine clearance 15&#8211;49&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery and prophylaxis of atherothrombotic events in acute coronary syndrome</i>, use with caution if creatinine clearance 15&#8211;29&#8239;mL/ minute.</p>\n<p>Use with caution if concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature).</p>\n<p>Avoid if creatinine clearance less than 15&#8239;mL/minute; manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55850\" outputclass=\"monitoringRequirements\" parent=\"/drugs/rivaroxaban\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p>\n</sectiondiv>\n<sectiondiv>\n<p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP56182\" outputclass=\"directionsForAdministration\" rev=\"1.7\" parent=\"/drugs/rivaroxaban\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Tablets may be crushed and mixed with water or apple puree just before administration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57177\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.13\" parent=\"/drugs/rivaroxaban\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Low-dose rivaroxaban, in combination with aspirin alone <i>or</i> aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers. Treatment should be started as soon as possible after the patient has been stabilised following the acute coronary event, at the earliest 24 hours after admission to hospital, and at the time when parenteral anticoagulation therapy would normally be discontinued; the usual duration of treatment is 12 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55805\" outputclass=\"nationalFunding\" rev=\"1.32\" parent=\"/drugs/rivaroxaban\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA170</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (April 2009)</p>\r\n<p>Rivaroxaban is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA170\">www.nice.org.uk/TA170</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA256</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation (May 2012)</p>\r\n<p>Rivaroxaban is an option for the prevention of stroke and systemic embolism (in accordance with its licensed indication) in patients with non-valvular atrial fibrillation and with at least one of the following risk factors:</p>\r\n<ul>\r\n<li>previous stroke or transient ischaemic attack</li>\r\n<li>congestive heart failure</li>\r\n<li>age &#8805;75 years</li>\r\n<li>diabetes mellitus</li>\r\n<li>hypertension</li>\r\n</ul>\r\n<p>The risks and benefits of rivaroxaban compared with warfarin should be discussed with the patient.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA256\">www.nice.org.uk/TA256</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA261</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism (July 2012)</p>\r\n<p>Rivaroxaban is an option for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thombosis and pulmonary embolism in adults after diagnosis of acute deep-vein thrombosis.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA261\">www.nice.org.uk/TA261</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA287</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013)</p>\r\n<p>Rivaroxaban is an option for treating pulmonary embolism and preventing recurrent deep-vein thrombosis and pulmonary embolism in adults.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA287\">www.nice.org.uk/TA287</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA335</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015)</p>\r\n<p>Rivaroxaban is an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in patients who have had an acute coronary syndrome with elevated cardiac biomarkers.</p>\r\n<p>The patient's risk of bleeding should be carefully assessed before treatment is initiated and the risks and benefits of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone should be discussed with the patient.</p>\r\n<p>A decision on continuation of treatment should be taken no later than 12 months after starting treatment.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA335\">www.nice.org.uk/TA335</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium </i>has advised (January 2012) that rivaroxaban (<i>Xarelto</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the prevention of stroke and systemic embolism in accordance with the licensed indication; use is restricted to patients with poor INR control despite compliance with coumarin anticoagulant therapy, or to patients who are allergic to, or unable to tolerate, a coumarin anticoagulant.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1513-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/rivaroxaban\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77297\" title=\"Tablet\" namespace=\"/drugs/rivaroxaban/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP98619\" namespace=\"/guidance/prescribing-in-dental-practice\" title=\"Prescribing in dental practice\" count=\"1\" rel=\"backlink\">Prescribing in dental practice</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"2\" rel=\"backlink\">Acute coronary syndromes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78291\" namespace=\"/treatment-summaries/arrhythmias\" title=\"Arrhythmias\" count=\"1\" rel=\"backlink\">Arrhythmias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78403\" namespace=\"/treatment-summaries/venous-thromboembolism\" title=\"Venous thromboembolism\" count=\"1\" rel=\"backlink\">Venous thromboembolism</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1136\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/rivaroxaban\" title=\"Rivaroxaban\" count=\"1\" rel=\"link\">Rivaroxaban</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77297\" namespace=\"/drugs/rivaroxaban/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP1513",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/rivaroxaban",
    "basename": "rivaroxaban",
    "title": "RIVAROXABAN",
    "interactants": [
        {
            "id": "bnf_int_1136",
            "label": "Rivaroxaban"
        }
    ],
    "vtmid": "442539005",
    "drugClassification": [
        "Factor Xa inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Rivaroxaban is a direct inhibitor of activated factor X (factor Xa).",
                "html": "<p>Rivaroxaban is a direct inhibitor of activated factor X (factor Xa).</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following knee replacement surgery",
                        "html": "Prophylaxis of venous thromboembolism following knee replacement surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "10 mg once daily for 2 weeks, to be started 6&#8211;10 hours after surgery.",
                        "html": "<p>10&#8239;mg once daily for 2 weeks, to be started 6&#8211;10 hours after surgery.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following hip replacement surgery",
                        "html": "Prophylaxis of venous thromboembolism following hip replacement surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "10 mg once daily for 5 weeks, to be started 6&#8211;10 hours after surgery.",
                        "html": "<p>10&#8239;mg once daily for 5 weeks, to be started 6&#8211;10 hours after surgery.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Initial treatment of deep-vein thrombosis",
                        "html": "Initial treatment of deep-vein thrombosis"
                    },
                    {
                        "textContent": "Initial treatment of pulmonary embolism",
                        "html": "Initial treatment of pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 15 mg twice daily for 21 days, to be taken with food.",
                        "html": "<p>Initially 15&#8239;mg twice daily for 21 days, to be taken with food.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Continued treatment of deep-vein thrombosis (following initial treatment)",
                        "html": "Continued treatment of deep-vein thrombosis (following initial treatment)"
                    },
                    {
                        "textContent": "Continued treatment of pulmonary embolism (following initial treatment)",
                        "html": "Continued treatment of pulmonary embolism (following initial treatment)"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent deep-vein thrombosis",
                        "html": "Prophylaxis of recurrent deep-vein thrombosis"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent pulmonary embolism",
                        "html": "Prophylaxis of recurrent pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "20 mg once daily, to be taken with food.",
                        "html": "<p>20&#8239;mg once daily, to be taken with food.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age &#8805; 75 years, or diabetes mellitus",
                        "html": "Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age &#8805; 75 years, or diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "20 mg once daily, to be taken with food.",
                        "html": "<p>20&#8239;mg once daily, to be taken with food.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of atherothrombotic events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel)",
                        "html": "Prophylaxis of atherothrombotic events in acute coronary syndrome (with aspirin alone or aspirin and clopidogrel)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg twice daily usual duration 12 months.",
                        "html": "<p>2.5&#8239;mg twice daily usual duration 12 months.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "For information on changing from, or to, other anticoagulants&#8212;consult product literature.",
                "html": "<p>For information on changing from, or to, other anticoagulants&#8212;consult product literature.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active bleeding",
                "html": "Active bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "in acute coronary syndrome&#8212;previous stroke",
                "html": "in <i>acute coronary syndrome</i>&#8212;previous stroke"
            },
            {
                "type": "contraindications",
                "textContent": "in acute coronary syndrome&#8212;transient ischaemic attack",
                "html": "in <i>acute coronary syndrome</i>&#8212;transient ischaemic attack"
            },
            {
                "type": "contraindications",
                "textContent": "malignant neoplasms",
                "html": "malignant neoplasms"
            },
            {
                "type": "contraindications",
                "textContent": "oesophageal varices",
                "html": "oesophageal varices"
            },
            {
                "type": "contraindications",
                "textContent": "recent brain surgery",
                "html": "recent brain surgery"
            },
            {
                "type": "contraindications",
                "textContent": "recent gastro-intestinal ulcer",
                "html": "recent gastro-intestinal ulcer"
            },
            {
                "type": "contraindications",
                "textContent": "recent intracranial haemorrhage",
                "html": "recent intracranial haemorrhage"
            },
            {
                "type": "contraindications",
                "textContent": "recent ophthalmic surgery",
                "html": "recent ophthalmic surgery"
            },
            {
                "type": "contraindications",
                "textContent": "recent spine surgery",
                "html": "recent spine surgery"
            },
            {
                "type": "contraindications",
                "textContent": "significant risk of major bleeding",
                "html": "significant risk of major bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "vascular aneurysm",
                "html": "vascular aneurysm"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait at least 18 hours after rivaroxaban dose before removing catheter and do not give next dose until at least 6 hours after catheter removal)",
                "html": "Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait at least 18 hours after rivaroxaban dose before removing catheter and do not give next dose until at least 6 hours after catheter removal)"
            },
            {
                "type": "cautions",
                "textContent": "bronchiectasis",
                "html": "bronchiectasis"
            },
            {
                "type": "cautions",
                "textContent": "prosthetic heart valve (efficacy not established)",
                "html": "prosthetic heart valve (efficacy not established)"
            },
            {
                "type": "cautions",
                "textContent": "risk of bleeding",
                "html": "risk of bleeding"
            },
            {
                "type": "cautions",
                "textContent": "rivaroxaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy",
                "html": "rivaroxaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy"
            },
            {
                "type": "cautions",
                "textContent": "severe hypertension",
                "html": "severe hypertension"
            },
            {
                "type": "cautions",
                "textContent": "vascular retinopathy",
                "html": "vascular retinopathy"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (rivaroxaban).\n\nCaution in concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Appendix 1 (rivaroxaban).</p><p>Caution in concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pain in extremities",
                        "html": "pain in extremities",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "renal impairment",
                        "html": "renal impairment",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Angioedema",
                        "html": "Angioedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dry mouth",
                        "html": "dry mouth",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "syncope",
                        "html": "syncope",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocythaemia",
                        "html": "thrombocythaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Jaundice",
                        "html": "Jaundice",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;toxicity in <i>animal</i> studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in liver disease with coagulopathy.",
                "html": "<p>Avoid in liver disease with coagulopathy.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "For treatment of deep-vein thrombosis or pulmonary embolism and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, initially 15 mg twice daily for 21 days, then 20 mg once daily (but consider reducing to 15 mg once daily if risk of bleeding outweighs risk of recurrent deep-vein thrombosis or pulmonary embolism) if creatinine clearance 15&#8211;49 mL/minute.\n\nFor prophylaxis of stroke and systemic embolism in atrial fibrillation, reduce dose to 15 mg once daily if creatinine clearance 15&#8211;49 mL/minute.",
                "html": "<p>For <i>treatment of deep-vein thrombosis or pulmonary embolism and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism</i>, initially 15&#8239;mg twice daily for 21 days, then 20&#8239;mg once daily (but consider reducing to 15&#8239;mg once daily if risk of bleeding outweighs risk of recurrent deep-vein thrombosis or pulmonary embolism) if creatinine clearance 15&#8211;49&#8239;mL/minute.</p><p>For <i>prophylaxis of stroke and systemic embolism in atrial fibrillation,</i> reduce dose to 15&#8239;mg once daily if creatinine clearance 15&#8211;49&#8239;mL/minute.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For prophylaxis of venous thromboembolism following knee or hip replacement surgery and prophylaxis of atherothrombotic events in acute coronary syndrome, use with caution if creatinine clearance 15&#8211;29 mL/ minute.\n\nUse with caution if concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature).\n\nAvoid if creatinine clearance less than 15 mL/minute; manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance.",
                "html": "<p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery and prophylaxis of atherothrombotic events in acute coronary syndrome</i>, use with caution if creatinine clearance 15&#8211;29&#8239;mL/ minute.</p><p>Use with caution if concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature).</p><p>Avoid if creatinine clearance less than 15&#8239;mL/minute; manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.",
                "html": "<p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "No routine anticoagulant monitoring required (INR tests are unreliable).",
                "html": "<p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Tablets may be crushed and mixed with water or apple puree just before administration.",
                "html": "<p>Tablets may be crushed and mixed with water or apple puree just before administration.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Low-dose rivaroxaban, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers. Treatment should be started as soon as possible after the patient has been stabilised following the acute coronary event, at the earliest 24 hours after admission to hospital, and at the time when parenteral anticoagulation therapy would normally be discontinued; the usual duration of treatment is 12 months.",
                "html": "<p>Low-dose rivaroxaban, in combination with aspirin alone <i>or</i> aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers. Treatment should be started as soon as possible after the patient has been stabilised following the acute coronary event, at the earliest 24 hours after admission to hospital, and at the time when parenteral anticoagulation therapy would normally be discontinued; the usual duration of treatment is 12 months.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA170",
                        "label": "www.nice.org.uk/TA170"
                    }
                ],
                "fundingIdentifier": "NICE TA170",
                "textContent": "Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (April 2009) Rivaroxaban is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.\n\nwww.nice.org.uk/TA170",
                "html": "<p outputclass=\"title\">Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (April 2009)</p> <p>Rivaroxaban is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA170\">www.nice.org.uk/TA170</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA256",
                        "label": "www.nice.org.uk/TA256"
                    }
                ],
                "fundingIdentifier": "NICE TA256",
                "textContent": "Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation (May 2012) Rivaroxaban is an option for the prevention of stroke and systemic embolism (in accordance with its licensed indication) in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: previous stroke or transient ischaemic attack congestive heart failure age &#8805;75 years diabetes mellitus hypertension The risks and benefits of rivaroxaban compared with warfarin should be discussed with the patient.\n\nwww.nice.org.uk/TA256",
                "html": "<p outputclass=\"title\">Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation (May 2012)</p> <p>Rivaroxaban is an option for the prevention of stroke and systemic embolism (in accordance with its licensed indication) in patients with non-valvular atrial fibrillation and with at least one of the following risk factors:</p> <ul> <li>previous stroke or transient ischaemic attack</li> <li>congestive heart failure</li> <li>age &#8805;75 years</li> <li>diabetes mellitus</li> <li>hypertension</li> </ul> <p>The risks and benefits of rivaroxaban compared with warfarin should be discussed with the patient.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA256\">www.nice.org.uk/TA256</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA261",
                        "label": "www.nice.org.uk/TA261"
                    }
                ],
                "fundingIdentifier": "NICE TA261",
                "textContent": "Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism (July 2012) Rivaroxaban is an option for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thombosis and pulmonary embolism in adults after diagnosis of acute deep-vein thrombosis.\n\nwww.nice.org.uk/TA261",
                "html": "<p outputclass=\"title\">Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism (July 2012)</p> <p>Rivaroxaban is an option for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thombosis and pulmonary embolism in adults after diagnosis of acute deep-vein thrombosis.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA261\">www.nice.org.uk/TA261</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA287",
                        "label": "www.nice.org.uk/TA287"
                    }
                ],
                "fundingIdentifier": "NICE TA287",
                "textContent": "Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013) Rivaroxaban is an option for treating pulmonary embolism and preventing recurrent deep-vein thrombosis and pulmonary embolism in adults.\n\nwww.nice.org.uk/TA287",
                "html": "<p outputclass=\"title\">Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013)</p> <p>Rivaroxaban is an option for treating pulmonary embolism and preventing recurrent deep-vein thrombosis and pulmonary embolism in adults.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA287\">www.nice.org.uk/TA287</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA335",
                        "label": "www.nice.org.uk/TA335"
                    }
                ],
                "fundingIdentifier": "NICE TA335",
                "textContent": "Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015) Rivaroxaban is an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in patients who have had an acute coronary syndrome with elevated cardiac biomarkers. The patient's risk of bleeding should be carefully assessed before treatment is initiated and the risks and benefits of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone should be discussed with the patient. A decision on continuation of treatment should be taken no later than 12 months after starting treatment.\n\nwww.nice.org.uk/TA335",
                "html": "<p outputclass=\"title\">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015)</p> <p>Rivaroxaban is an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in patients who have had an acute coronary syndrome with elevated cardiac biomarkers.</p> <p>The patient's risk of bleeding should be carefully assessed before treatment is initiated and the risks and benefits of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone should be discussed with the patient.</p> <p>A decision on continuation of treatment should be taken no later than 12 months after starting treatment.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA335\">www.nice.org.uk/TA335</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77297",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP98619",
                "label": "Prescribing in dental practice",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78291",
                "label": "Arrhythmias",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78403",
                "label": "Venous thromboembolism",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1136",
                "label": "Rivaroxaban",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77297",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}